The Cancer Letter asked David Challoner, emeritus vice president for health affairs at the University of Florida, to discuss the intricacies and effects of the FDA's 510(k) medical device approval process, and the parties that influence it.
On The Principles of SurgeryNoorchashm attributes his wife's complication in part to deficits in the gynecologists' surgical training.
On Oct. 17, 2013, a surgical instrument called a power morcellator tore into the uterus of Amy Reed, an anesthesiologist at Beth Israel Deaconess Medical Center, pulverizing what were believed to be benign fibroids.
FDA approved a new use for Lymphoseek Injection (technetium 99m tilmanocept), a radioactive diagnostic imaging agent, to determine the extent squamous cell carcinoma has spread in the body's head and neck region.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A dendritic cell-based immunotherapeutic vaccine increased median overall survival by about four months in a phase II placebo-controlled study in newly diagnosed glioblastoma multiforme.
In a phase III trial of patients with progressive radioiodine-refractory differentiated thyroid cancer, lenvatinib significantly extended progression-free survival compared to placebo.
A phase III trial demonstrated a 37 percent improvement in progression-free survival when using the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone compared to treatment with the same regimen with placebo in patients with relapsed or relapsed and refractory multiple myeloma.
Data from the phase III RESONATE trial showed that monotherapy ibrutinib significantly lengthened progression-free survival and overall survival compared to ofatumumab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia.
By priming pancreatic ductal adenocarcinomas with a therapeutic vaccine and a low-dose chemotherapy combination prior to surgery, researchers converted PDACs into cancers that may respond to immunotherapy.
